Talazoparib or APE1 inhibitor were demonstrated to induce critical antileukemic effects against selected primary CD34+ AML samples, and further experiments demonstrated that low dose talazoparib and APE1 inhibitor treatment enhanced the efficacy of decitabine against AML (Kohl et al., 2019). The gene discussed is APEX1; the disease is acute myeloid leukemia.